118 related articles for article (PubMed ID: 26603212)
1. Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.
Bennouna J; Moreno Vera SR
Future Oncol; 2016 Feb; 12(3):355-72. PubMed ID: 26603212
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
4. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
6. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
7. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
8. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
10. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
[TBL] [Abstract][Full Text] [Related]
11. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
12. The role of afatinib in the management of non-small cell lung carcinoma.
Yap TA; Popat S
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1529-39. PubMed ID: 23985030
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
14. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
15. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
16. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
[TBL] [Abstract][Full Text] [Related]
17. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
[TBL] [Abstract][Full Text] [Related]
18. Afatinib.
Wecker H; Waller CF
Recent Results Cancer Res; 2018; 211():199-215. PubMed ID: 30069769
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A
Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402
[TBL] [Abstract][Full Text] [Related]
20. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Köhler J; Schuler M
Onkologie; 2013; 36(9):510-8. PubMed ID: 24051929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
